SCHEDULE: State Street Discloses 5.1% Stake in Vanda Pharmaceuticals

State Street Corporation has reported beneficial ownership of 5.1% of Vanda Pharmaceuticals Inc. common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 3,015,562 shares of Vanda Pharmaceuticals Inc. common stock.
• This ownership represents 5.1% of the class of securities.
• The filing date is May 12, 2026, with the event date requiring the filing being March 31, 2026.
• State Street Corporation is identified as a holder of investment assets, with its subsidiaries SSGA FUNDS MANAGEMENT, INC., STATE STREET GLOBAL ADVISORS EUROPE LIMITED, STATE STREET GLOBAL ADVISORS LIMITED, and STATE STREET GLOBAL ADVISORS TRUST COMPANY involved.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on institutional ownership without providing performance data or strategic insights into Vanda Pharmaceuticals.

Positives

• State Street Corporation's investment indicates confidence in Vanda Pharmaceuticals Inc. from a major institutional investor.
• The filing confirms a significant institutional holding, which can sometimes lead to increased liquidity and analyst coverage.

Negatives

• The filing does not provide specific financial performance data for Vanda Pharmaceuticals Inc., only ownership stakes.
• The nature of State Street's involvement is as a passive investor, not an activist seeking to influence management.

Risks

• The filing does not explicitly mention any risks related to Vanda Pharmaceuticals Inc.'s business operations or financial health.
• Potential risks for Vanda Pharmaceuticals Inc. could include regulatory hurdles, clinical trial outcomes, or competitive pressures, none of which are detailed in this ownership filing.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Vanda Pharmaceuticals Inc.'s future performance. It solely reports on State Street Corporation's ownership stake.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings from large institutional investors like State Street Corporation are common and typically indicate passive investment stakes rather than active engagement in corporate control. This filing suggests State Street, through its asset management arms, holds a notable position in Vanda Pharmaceuticals, aligning with broader trends of institutional capital allocation in the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which may be viewed positively by some shareholders as a sign of institutional support.
• Management: The filing explicitly states the shares are not held for the purpose of influencing control, suggesting no immediate pressure from this holder on management decisions.
• Creditors: No direct impact on creditors is indicated by this ownership filing.

Next Steps

• State Street Corporation will continue to hold its shares in Vanda Pharmaceuticals Inc. in the ordinary course of business.
• Future filings will be made if ownership levels change significantly.

Key Dates

Keywords

Vanda Pharmaceuticals, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management